A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.

PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

August 31, 2026

Conditions
Reflux Esophagitis (RE)
Interventions
DRUG

Anaprazole + Rabeprazole placebo

Anaprazole 3 tablets (20 mg/tablet) + Rabeprazole placebo 1 tablet (0.16 g/tablet), administered orally 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.

DRUG

Rabeprazole + Anaprazole placebo

Rabeprazole 1 tablet (20 mg/tablet) + Anaprazole placebo 3 tablets (0.2 g/tablet), orally administered 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.

Trial Locations (1)

200433

RECRUITING

Shanghai Changhai Hospital, Shanghai

All Listed Sponsors
lead

Xuanzhu Biopharmaceutical Co., Ltd.

INDUSTRY